Immunovia AB (IMMVF) Price & Analysis

Compare

37 Followers

IMMVF Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.05 - $0.07

Previous CloseN/A

Volume500.00

Average Volume (3M)0.00

Market Cap

$11.36M

Enterprise Value$78.92M

Total Cash (Recent Filing)$25.32M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.19

Next Earnings

Aug 21, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding306,083,070

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)5.80

Price to Sales (P/S)0.00

P/FCF Ratio-1.08

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Immunovia AB News

PremiumCompany Announcements

Immunovia’s PancreaSure Gains Recognition at EDRN Workshop

7d ago

PremiumCompany Announcements

Immunovia AB Reports Q1 2025 Financials and Strategic Progress

14d ago

PremiumCompany Announcements

Immunovia AB Annual General Meeting Resolutions

14d ago

PremiumCompany Announcements

Immunovia Reports Q1 2025 Results and Hosts Webcast

14d ago

PremiumCompany Announcements

Immunovia AB Reports Interim Loss Amid Preparations for PancreaSure Launch

14d ago

PremiumCompany Announcements

Immunovia’s CLARITI Study Gains Recognition at Digestive Disease Week 2025

21d ago

PremiumThe Fly

Immunovia provides further data from VERIFI study of pancreatic cancer test

2M ago

PremiumCompany Announcements

Immunovia AB Reports Progress in Cancer Diagnostics

3M ago

See All IMMVF News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

― Mutual Funds

― Other Institutional Investors

100.00% Public Companies and

Individual Investors

Detailed Ownership Overview >

IMMVF FAQ

What was Immunovia AB’s price range in the past 12 months?

Immunovia AB lowest stock price was $0.05 and its highest was $0.07 in the past 12 months.

What is Immunovia AB’s market cap?

Immunovia AB’s market cap is $11.36M.

When is Immunovia AB’s upcoming earnings report date?

Immunovia AB’s upcoming earnings report date is Aug 21, 2025 which is in 85 days.

How were Immunovia AB’s earnings last quarter?

Immunovia AB released its earnings results on May 14, 2025. The company reported -$0.025 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.025.

Is Immunovia AB overvalued?

According to Wall Street analysts Immunovia AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunovia AB pay dividends?

Immunovia AB does not currently pay dividends.

What is Immunovia AB’s EPS estimate?

Immunovia AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immunovia AB have?

Immunovia AB has 306,083,070 shares outstanding.

What happened to Immunovia AB’s price movement after its last earnings report?

Immunovia AB reported an EPS of -$0.025 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Immunovia AB?

Currently, no hedge funds are holding shares in IMMVF

Company Description

Immunovia AB

Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

IMMVF Company Deck

IMMVF Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant progress in test development and financial management, with successful analytical validation and a promising rights issue. However, challenges remain with increased cash burn, limited initial revenue, and regulatory hurdles. The company is optimistic about its strategic plans for 2025, particularly the U.S. launch.Read More>

IMMVF Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2021","6":"Jul<br/>2021","9":"Oct<br/>2021","12":"Dec<br/>2021","25":"Dec<br/>2022"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.24,3.913846153846154,3.5876923076923077,3.2615384615384615,2.9353846153846153,2.609230769230769,2.2830769230769232,1.956923076923077,1.6307692307692307,1.3046153846153845,0.9784615384615383,0.652307692307692,0.32615384615384624,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.87,"date":1609459200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.87,"date":1612137600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.87,"date":1614556800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.87,"date":1617235200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.87,"date":1619827200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.87,"date":1622505600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.87,"date":1625097600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.39,"date":1627776000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.32,"date":1630454400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.68,"date":1633046400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.41,"date":1635724800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.24,"date":1638316800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.24,"date":1638316800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >